AzTrials
AzTrials

Critical IllnessCONNECTNCT07830043

Patient Characterization Panel to Improve Satisfaction With the Intensive Care Unit Stay (CONNECT)

A study testing Patient-as-a-Person Characterization Panel with Staff Training and Standard ICU Care in people with Critical Illness and Family Satisfaction, run by University of Sao Paulo General Hospital at 2 sites in Brazil.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Intensive care units (ICUs) present unique challenges to humanized, person-centered care. The severity of illness and the demands of complex technical management can displace attention from patients as individuals, making it harder to build meaningful connections with patients and their families. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Patient-as-a-Person Characterization Panel with Staff Training and Standard ICU Care
Could I receive a placebo?
No, everyone receives an active treatment
How many people
966 participants
Where
2 sitesBrazil
Study dates
Oct 2026to Mar 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patient admitted to a participating ICU for more than 48 hours.
  • Patient aged 18 years or older.
  • Patient's family member or legally designated surrogate aged 18 years or older, and identifiable at the time of enrollment.
  • Patient and/or family member/surrogate able to speak and understand Portuguese.
  • Signature of the Informed Consent Form (ICF) by the family member or surrogate after 48 hours of ICU admission, and by the patient once conscious and oriented (also after 48 hours of ICU admission).

Who cannot join

  • ICU stay of 48 hours or less.
  • No identifiable family member or legally designated surrogate.
  • Patient or family member/surrogate under 18 years of age.
  • Unable to speak or understand Portuguese.
  • Pregnant patient.
  • Patient deprived of liberty (incarcerated).
  • Refusal to sign the Informed Consent Form.

Trial locations and contacts

2 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Daniel N Forte, MD; PhD contact

+55 (11) 99914-5458

daniel.forte@hc.fm.usp.br

Brazil2 sites
  • Monte Klinikum Hospital

    Fortaleza, Ceará, 60160-140

    Sabrina CC Ribeiro, MD; PhD, +5511996296717, sabrinaccr@gmail.com

  • Clinical Hospital of the University of São Paulo Medical School- Central Institute

    São Paulo, São Paulo, 05403-000

    Amanda P Botega, MD, +5535991554257, amandapbotega@gmail.com

Other trials in Brazil

About this study

Official title: Effect of a "Patient as a Person" Characterization Panel on Family and Patient Satisfaction With the Intensive Care Unit (ICU) Stay: A Stepped-Wedge Cluster Randomized Trial (CONNECT)

Intensive care units (ICUs) present unique challenges to humanized, person-centered care. The severity of illness and the demands of complex technical management can displace attention from patients as individuals, making it harder to build meaningful connections with patients and their families.

This trial tests a simple, low-cost bedside intervention: a structured panel. The "Patient as a Person" panel, placed near each patient's bed. The care team, together with the patient and family, records personal information about who the patient is outside the hospital: how they prefer to be addressed, their interests, and what matters most to them. Physicians, nurses, and physical therapists receive training on how to incorporate this information into daily care interactions.

Read more

The study follows a stepped-wedge cluster randomized design across six ICUs in Brazil: four at Clinical Hospital of the University of São Paulo Medical School (São Paulo); and two at Monte Klinikum Hospital (Fortaleza). All ICUs begin with a control period of standard care. Every two months, one ICU transitions to the intervention, until all six units have adopted the panel. The total study duration is 14 months. Each ICU serves as its own control together with the comparison between ICUs for periods with and without the intervention. Questionnaire administrators are blinded to whether a given hospitalization occurred during the control or intervention phase.

Eligible participants are adult patients (≥18 years) admitted to a participating ICU for more than 48 hours, and their family members or legal representatives (≥18 years). Pregnant women, incarcerated individuals, and non-Portuguese speakers are excluded. Informed consent is obtained from family members after 48 hours of admission, and from patients once they are alert and oriented.

The primary outcome is family satisfaction with the ICU stay, assessed using the Family Satisfaction with Care in the Intensive Care Unit Questionnaire (FS-ICU 24R questionnaire), a validated intrument adapted for use in Brazil. Secondary outcomes include patient-reported quality of communication, ICU staff perceptions of the panel, and symptoms of anxiety and depression in family members at three months. Estimated enrollment is 966 patients.

The intervention involves no physical procedures. Data are coded and de-identified. Results will be published regardless of outcome.

Read the detailed description

Study design:

Study CONNECT is a prospective, open-label, multicenter clinical trial with cluster-level randomization, using a stepped-wedge design. The randomization unit is the Intensive Care Unit (cluster). All clusters begin in the control phase and cross over to the intervention in a staggered, randomly determined sequence, one cluster every two months, with no transition period between phases. The study runs for 14 months, comprising seven two-month periods (including a baseline period in which all Intensive Care Units (ICUs) remain in the control condition). Each cluster's allocation sequence is disclosed to researchers and staff one week before its respective phase transition. Blinding of patients, family members, and care staff is not feasible given the nature of the intervention; however, personnel responsible for administering outcome questionnaires are blinded to the period the patient was admitted to the ICU (i.e., control vs. intervention period) and to the details of each patient's ICU stay, to minimize information bias.

Settings:

The trial is conducted in six ICUs across two hospitals in Brazil: four ICUs at Clinical Hospital of the University of São Paulo Medical School (HC-FMUSP), São Paulo, a public, academic, quaternary-care hospital; and two ICUs at Monte Klinikum Hospital, Fortaleza, a private, tertiary, non-academic hospital. This combination was selected to ensure diversity in hospital type, patient and family sociodemographic profiles, clinical case mix, and care team organization. All participating ICUs use closed (single-patient) rooms.

Intervention:

The intervention is the "Patient as a Person" Characterization Panel (PCPP) named "Come to Know me", a structured bedside instrument inspired by the "Get to Know Me" poster developed at Massachusetts General Hospital. The PCPP comprises 19 fields completed collaboratively by the multidisciplinary care team (medicine, nursing, and physical therapy) together with the patient and family members, and may include photographs. The panel documents the patient's identity, personal preferences, biographical details, and what matters most to them outside the hospital, making this information visible and accessible to the entire care team. The panel is displayed near the patient's bedside in a location that preserves data privacy. Implementation is preceded by structured staff training delivered prior to each ICU's phase transition, supplemented by monthly retraining sessions and printed and online instructional materials throughout the intervention period.

Control arm:

In the control phase, participating ICUs maintain standard care practices. No version of the PCPP or related training is introduced.

Eligibility:

Patients are eligible if they are 18 years of age or older and have been admitted to a participating ICU for more than 48 hours. Their family members or legally designated representatives, also 18 years of age or older, are eligible as co-participants. Exclusion criteria are pregnancy, incarceration, and inability to communicate in Portuguese. Written informed consent is obtained from family members after 48 hours of ICU admission, and from patients once they are alert and oriented after 48 hours of ICU admission. In case patients are transferred between study ICUs or readmitted, they are assigned to the arm/period of their index ICU admission (intention-to-treat).

Outcomes and data collection:

The primary outcome is family satisfaction with the ICU stay, assessed using the Family Satisfaction with Care in the Intensive Care Unit Questionnaire (FS-ICU 24R questionnaire), a validated instrument adapted for use in Brazil. Secondary outcomes include: patient-perceived quality of communication (Quality of Communication Questionnaire, QOC); ICU staff perceptions of the PCPP, assessed via a quantitative-qualitative questionnaire developed by the study team; and symptoms of anxiety and depression in patients (where feasible) and family members, assessed using the Hospital Anxiety and Depression Scale (HADS) at three months after ICU discharge. All questionnaires are administered in Brazilian Portuguese by a blinded assessor. Sociodemographic and clinical data, including age, sex, marital status, educational level, self-reported race/color, religion, admission diagnosis, ICU length of stay, ICU and hospital outcome, decisions regarding withholding or withdrawing life-sustaining treatment, and Simplified Acute Physiology Score 3 (SAPS 3) severity score, are collected via REDCap (version 14.5.21) for sample characterization.

Sample size:

The sample size was calculated using the steppedwedge command in Stata version 13.1, assuming a two-sided alpha of 5%, 80% power, a mean of 23 eligible patients per two-month period per ICU, a baseline mean FS-ICU 24R score of 75 points (SD 30), an expected absolute increase of 7.5 points (corresponding to a 10% relative increase, from 75 to 82.5 points), and a coefficient of variation (k) of 0.25. This yields an estimated total of 966 patients (6 ICUs × 7 periods × 23 patients per period). As is standard in stepped-wedge designs, study completion is determined by the elapsed time across the seven predefined periods, not by reaching a specific patient count.

Statistical analysis:

The primary analysis follows the intention-to-treat principle, with two-sided tests and a 5% significance level. The primary outcome (FS-ICU 24R questionnaire), analyzed at the individual patient level, will be estimated using a generalized linear mixed model (GLMM), with intervention status, calendar time period, and pre-specified adjustment covariates (SAPS 3 score, clinical versus surgical profile, ICU region, and number of ICU beds) as fixed effects. The error distribution will be selected based on best fit to the data (Poisson, negative binomial, or alternative distributions). Random effects include a per-cluster intercept, capturing between-ICU variability, and, where warranted, an ICU-by-period interaction term, capturing intra-cluster temporal correlation. If a substantial proportion of primary outcome data are missing, multiple imputation by chained equations (MICE) will be applied under the missing-at-random (MAR) assumption. Pre-specified subgroup analyses will assess potential effect modification by patient severity (SAPS 3), ICU outcome (discharge versus death), and presence or absence of a terminal or advanced chronic illness, using the same GLMM with an intervention-by-subgroup interaction term. A statistical analysis plan (SAP) will be finalized and submitted for publication before database lock.

Being tested
Patient-as-a-Person Characterization Panel with Staff Training, Standard ICU Care
Keywords
Critical Care, Humanization of Assistance, Patient-Centered Care, Clinical Trial, Family
Medical subject headings
Critical Illness

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Patient-as-a-Person Characterization Panel with Staff TrainingBehavioural

    The Patient-as-a-Person Characterization Panel (PCPP) "Come to Know Me" is a structured 19-item instrument completed collaboratively by the multidisciplinary care team (medicine, nursing, and physical therapy) together with the patient and/or family members, and may include photographs. The panel documents the patient's identity, personal preferences, and biographical details, making this information visible to all members of the care team. It is displayed within the patient's private Intensive Care Unit (ICU) room in a location that preserves data privacy, and is completed as part of routine clinical care. Prior to each cluster's crossover, all relevant staff receive structured training on panel use; monthly retraining sessions and printed and online instructional materials are provided throughout the intervention period. Patients in the intervention arm also receive standard ICU care as practiced at each participating unit.

  • Standard ICU CareOther

    During the control period, each participating ICU maintains its routine standard of care without any study-related additions. The Patient-as-a-Person Characterization Panel is not used, and no related staff training is provided. Standard care practices vary by site and are not modified by the study.

Study groups in NCT07830043
Study groupRoleWhat they receive
Intervention Period (Post-Crossover)ExperimentalA cluster (Intensive Care Unit) that has crossed over to the intervention period, according to its randomly allocated sequence, implements the Patient-as-a-Person Characterization Panel (PCPP) for all patients admitted from that point until study completion, with no reversion to standard care. Implementation is preceded by structured staff training and reinforced through monthly retraining sessions, supported by printed and online instructional materials.
Receives: Behavioral: Patient-as-a-Person Characterization Panel with Staff Training
Control Period (Pre-Crossover)OtherUntil a cluster (Intensive Care Unit) reaches its designated crossover point according to the randomly allocated sequence, it provides standard ICU care. Patients admitted during this period are not exposed to the Patient-as-a-Person Characterization Panel. This condition applies only until the cluster's crossover, after which it transitions permanently to the intervention.
Receives: Other: Standard ICU Care

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Family/surrogate satisfaction with the ICU stay

    Family or surrogate satisfaction is assessed using the Family Satisfaction with Care in the Intensive Care Unit 24R questionnaire (FS-ICU 24R), validated and culturally adapted for Brazil. Three summary scores are derived: Satisfaction with Care, Satisfaction with Decision Making, and Overall Satisfaction, each ranging from 0 to 100, with higher scores indicating greater satisfaction. The FS-ICU 24R is administered by a blinded assessor to all eligible family members or surrogates 15 days after ICU outcome (discharge or death), or 28 days after enrollment, whichever occurs first.

    The Informed Consent Form (ICF) is collected from the family member or surrogate 48 hours after ICU admission. Questionnaire administration is classified as a research procedure; the panel itself ("Come to Know me") is implemented as part of routine clinical care during the intervention period and does not require separate consent.

    Measured: 15 days after ICU discharge or death, or Day 28 after enrollment, whichever occurs first

Secondary outcomes (3)
  1. Patient-perceived quality of communication in the ICU

    Patient-perceived quality of communication is assessed using the Quality of Communication Questionnaire (QOC), translated into Portuguese and validated for cultural use in Brazil. The score is calculated as the mean of the 13 items (items 1-6 for the General Communication subscale, and items 7-13 for the End-of-Life Communication subscale), ranging from 0 to 10 each, with higher scores indicating better perceived quality of communication. The QOC is administered by a blinded assessor 15 days after ICU discharge, or 28 days after enrollment, whichever occurs first, and only in patients assessed as conscious and oriented at the time of administration.

    Measured: 15 days after ICU discharge, or Day 28 after enrollment, whichever occurs first.

  2. ICU staff perception following first completion of the Patient-as-a-Person Characterization Panel

    Staff perception is assessed using a structured questionnaire developed by the study team, administered via REDCap (version 14.5.21). The questionnaire evaluates perceived difficulty in completing the panel, barriers to its use in clinical practice, its potential contribution to patient care, and open comments. It is made available via QR code posted in the ICU or via a link sent by the research team, and is completed only once, upon the staff member's first use of the panel.

    Measured: Day 1

  3. Anxiety and depression in patients (where feasible) and family members/surrogates

    Symptoms of anxiety and depression are assessed using the Hospital Anxiety and Depression Scale (HADS), validated and adapted for the Brazilian population. The HADS is administered 3 months after ICU outcome (discharge or death) to ICU survivors and to family members or surrogates of both surviving and deceased patients.

    Measured: 3 months after ICU outcome (discharge or death)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Sep 2026
  2. Study startOct 2026 (estimated)
  3. Primary completionDec 2027 (estimated)
  4. Study completionMar 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Crossover
Model description
Prospective, open-label, multicenter, cluster-randomized trial conducted across 6 Intensive Care Units (ICUs), using a stepped-wedge design. All participating ICUs begin in the control phase and cross over to the intervention in a staggered, randomized sequence, one cluster every two months, with no transition period between phases, until all clusters have been exposed to the intervention. The design enables each ICU to serve as its own control, while also allowing comparisons between intervention and control periods across ICUs and assessment of temporal trends over time.
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
966 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07830043
Sponsor's protocol ID
89006725.0.1001.0068
Acronym
CONNECT
Status last verified
Sep 2026
First submitted
1 Sep 2026
Last updated
21 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: De-identified individual participant data underlying the primary study results will be shared with qualified researchers following approval of a methodologically sound proposal, subject to a data use agreement and consistency with the original participant consent. Supporting documents will include the study protocol, statistical analysis plan, informed consent form, and analytic code.

Questions about this trial

What is this clinical trial studying?

A study testing Patient-as-a-Person Characterization Panel with Staff Training and Standard ICU Care in people with Critical Illness and Family Satisfaction, run by University of Sao Paulo General Hospital at 2 sites in Brazil.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 21 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Amanda P Botega, MD (+55 (35) 99155-4257, amandapbotega@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Family/surrogate satisfaction with the ICU stay (time frame: 15 days after ICU discharge or death, or Day 28 after enrollment, whichever occurs first). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Sep 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in